Curanex Pharmaceuticals Inc Common Stock (CURX) - Total Assets
Based on the latest financial reports, Curanex Pharmaceuticals Inc Common Stock (CURX) holds total assets worth $14.48 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CURX net asset value for net asset value and shareholders' equity analysis.
Curanex Pharmaceuticals Inc Common Stock - Total Assets Trend (2022–2024)
This chart illustrates how Curanex Pharmaceuticals Inc Common Stock's total assets have evolved over time, based on quarterly financial data.
Curanex Pharmaceuticals Inc Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Curanex Pharmaceuticals Inc Common Stock's total assets of $14.48 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how Curanex Pharmaceuticals Inc Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Curanex Pharmaceuticals Inc Common Stock (CURX) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Curanex Pharmaceuticals Inc Common Stock's current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2022.
- Cash Position: Cash and equivalents constituted 28.8% of total assets in 2024, up from 23.8% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Curanex Pharmaceuticals Inc Common Stock Competitors by Total Assets
Key competitors of Curanex Pharmaceuticals Inc Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Curanex Pharmaceuticals Inc Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 77.53 | 102.04 | 1110.65 |
| Quick Ratio | 77.53 | 102.04 | 1110.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $14.23 Million | $565.85K | $665.79K |
Curanex Pharmaceuticals Inc Common Stock - Advanced Valuation Insights
This section examines the relationship between Curanex Pharmaceuticals Inc Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.56 |
| Latest Market Cap to Assets Ratio | 15.43 |
| Asset Growth Rate (YoY) | 596.5% |
| Total Assets | $517.93K |
| Market Capitalization | $7.99 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Curanex Pharmaceuticals Inc Common Stock's assets at a significant premium (15.43x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Curanex Pharmaceuticals Inc Common Stock's assets grew by 596.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Curanex Pharmaceuticals Inc Common Stock (2022–2024)
The table below shows the annual total assets of Curanex Pharmaceuticals Inc Common Stock from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $517.93K | +596.47% |
| 2023-12-31 | $74.37K | +626.80% |
| 2022-12-31 | $10.23K | -- |
About Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma… Read more